Physician profile
Prisila A Foss
NPI 1992731517
$1,606.93
in general payments reported to CMS, 2019-2025
27 companies · $32.52 in 2025
The $32.52 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.41 · 2021: $684 · 2022: $752 · 2023: $126 · 2025: $32.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $630.62 | 2021-2022 | |
| Emd Serono, INC. | $169.23 | 2021-2023 | Mavenclad |
| Merz Pharmaceuticals, LLC | $102.64 | 2021-2022 | |
| Kyowa Kirin, INC. | $74.54 | 2021 | |
| Jazz Pharmaceuticals INC. | $72.36 | 2022 | |
| Lundbeck LLC | $70.77 | 2021-2023 | Vyepti |
| Sk Life Science, INC. | $45.27 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.57 | 2022 | |
| Avanir Pharmaceuticals, INC. | $38.73 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.06 | 2022 | |
| Becton, Dickinson and Company | $32.52 | 2025 | Acumen Iq |
| Biogen, INC. | $29.82 | 2022 | |
| Argenx US, INC. | $26.39 | 2022 | |
| Acorda Therapeutics, INC | $21.92 | 2023 | Inbrija, Ampyra |
| Medtronic, INC. | $21.83 | 2023 | Plasmablade(Tm) |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $21.26 | 2022 | |
| Genzyme Corporation | $20.51 | 2022 | |
| Ucb, INC. | $18.53 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.90 | 2023 | Lyvispah |
| Banner Life Sciences, LLC | $17.70 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.19 | 2021 | |
| Grifols USA, LLC | $15.36 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.46 | 2022 | |
| Currax Pharmaceuticals LLC | $13.84 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $12.41 | 2020 | |
| Alnylam Pharmaceuticals INC. | $12.35 | 2021 | |
| Endo Pharmaceuticals INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prisila Foss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.